NR3C2 and prostate cancer: In another phase I trial that evaluated abiraterone acetate in patients with castrate-resistant prostate cancer who were previously on ketoconazole, MES occurred, which was treated with an aldosterone receptor antagonist [9]; however, the adjunct glucocorticoid therapy also had the additional effect of improving tumor response, as well as ameliorating the incidence of MES occurrence [10,11].